Literature DB >> 29525405

Clinicopathological analysis of Large Cell Lung Carcinomas definitely diagnosed according to the New World Health Organization Criteria.

Yalan Bi1, Yang Qu2, Zhiyong Liang1, Zichen Liu2, Hui Zhang1, Xiaolong Liang1, Yufeng Luo1, Jinling Cao1, Haiqing Zhang3, Ruie Feng4.   

Abstract

OBJECTIVE: The definition of large cell lung carcinoma (LCC) has undergone an extensive modification in the World Health Organization (WHO) Classification (2015). Present study aimed to investigate the clinicopathological characteristics of patients diagnosed as LCC according to current WHO criteria.
METHODS: LCCs diagnosed based on the previous WHO classification were reevaluated, and 17 cases of LCC were finally identified at Peking Union Medical College Hospital and Beijing Chest Hospital between 2009 and 2015. The clinicopathologic features were examined and EGFR and KRAS mutations were tested. Survival of the patients was analyzed by Kaplan-Meier method.
RESULTS: The median age of the patients was 64 years (range: 40-78). Most patients were male (64.7%) and about half of the patients were at TNM stage III (47.1%). Morphologically, most cases (70.6%) were classic LCC. All patients were treated by lobectomy plus lymph node dissection, 2 with bi-lobectomy and 1 with complex lobectomy, and the other 2 patients were further treated by partial pericardiotomy. Ten patients received postoperative chemotherapy, while only 3 patients were treated with radiotherapy after surgery. Molecular analysis showed two cases of EGFR mutation (L858R) but without non-overlapping KRAS mutation. The 3-year overall survival rate was 48.4 ± 15.1%. Chemotherapy was the only predictive factor that is associated with the prognosis of the patients (P = 0.003).
CONCLUSION: The clinicopathological characteristics of 17 cases of stringently diagnosed LCC were retrospectively analyzed. LCC in our study showed aggressive behavior with high recurrence and metastasis and poor prognosis. Chemotherapy was only predictive factor that is significantly associated with the prognosis of the patients. Future studies based on a larger series and long term follow-up are still needed to characterize it further.
Copyright © 2018 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Clinicopathological characteristics; EGFR mutation; Large cell lung carcinoma (LCC); Survival; World Health Organization (WHO) 2015 Classification

Mesh:

Substances:

Year:  2018        PMID: 29525405     DOI: 10.1016/j.prp.2018.02.006

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  3 in total

1.  Clinical characteristics and prognosis of pulmonary large cell carcinoma: A population-based retrospective study using SEER data.

Authors:  Liu Xiaochuan; Yu Jiangyong; Zhang Ping; Wu Xiaonan; Li Lin
Journal:  Thorac Cancer       Date:  2020-04-16       Impact factor: 3.500

2.  Pulmonary large cell carcinoma with neuroendocrine morphology shows genetic similarity to large cell neuroendocrine carcinoma.

Authors:  Zuoyu Liang; Weiya Wang; Qianrong Hu; Ping Zhou; Ying Zhang; Yuan Tang; Qian Wu; Yiyun Fu; Xue Li; Yang Shao; Lili Jiang
Journal:  Diagn Pathol       Date:  2022-02-10       Impact factor: 2.644

3.  Clinical characteristics and treatments of large cell lung carcinoma: a retrospective study using SEER data.

Authors:  Qidong Tai; Lei Zhang; Xuefei Hu
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.